PDF(Pubmed)
Abstract：
BACKGROUND: Describe complications and clinical outcomes of heavy silicone oil (HSO) Oxane HD® use as an alternative to overcome the challenges of performing vitrectomy to treat tractional and rhegmatogenous retinal detachments with proliferative vitreoretinopathy (PVR).
METHODS: A retrospective, observational study was performed on patients from one center from August 2014 to Aug 2023. It was included patients who underwent surgery using HSO Oxane HD® to treat rhegmatogenous retinal detachment with PVR or mixed tractional and rhegmatogenous diabetic retinal detachment. Severely ill patients who could not attend to follow up were excluded. The primary outcome was successful retinal attachment at first postoperative month. A descriptive analysis was performed.
RESULTS: Among the 31 patients, 29 (93.5%) underwent surgeries due to rhegmatogenous retinal detachment and two (6.5%) for diabetic retinal detachment. The primary anatomic success was achieved in 27 (87.1%) patients. At the final visit, 17 (56.6%) had vision better than 20/400 (range, 20/30 to light perception). The vision was stable or improved in 22 (76.8%) patients at the end of follow-up. Nineteen (61.3%) patients required hypotensive eye drops after HSO use and twelve (38.7%) still required hypotensive eye drops at the final follow-up; three (9.7%) patients required additional glaucoma surgeries.
CONCLUSIONS: HSO is safe and useful for complex retinal detachments cases specially with inferior tears and PVR. Ocular hypertension is frequent and usually clinically controlled with hypotensive eyedrops. Close postoperatively follow-up is advised due to the ocular complications, particularly elevated intraocular pressure and emulsification.
METHODS: A retrospective, observational study was performed on patients from one center from August 2014 to Aug 2023. It was included patients who underwent surgery using HSO Oxane HD® to treat rhegmatogenous retinal detachment with PVR or mixed tractional and rhegmatogenous diabetic retinal detachment. Severely ill patients who could not attend to follow up were excluded. The primary outcome was successful retinal attachment at first postoperative month. A descriptive analysis was performed.
RESULTS: Among the 31 patients, 29 (93.5%) underwent surgeries due to rhegmatogenous retinal detachment and two (6.5%) for diabetic retinal detachment. The primary anatomic success was achieved in 27 (87.1%) patients. At the final visit, 17 (56.6%) had vision better than 20/400 (range, 20/30 to light perception). The vision was stable or improved in 22 (76.8%) patients at the end of follow-up. Nineteen (61.3%) patients required hypotensive eye drops after HSO use and twelve (38.7%) still required hypotensive eye drops at the final follow-up; three (9.7%) patients required additional glaucoma surgeries.
CONCLUSIONS: HSO is safe and useful for complex retinal detachments cases specially with inferior tears and PVR. Ocular hypertension is frequent and usually clinically controlled with hypotensive eyedrops. Close postoperatively follow-up is advised due to the ocular complications, particularly elevated intraocular pressure and emulsification.
摘要：
背景：描述重硅油（HSO）OxaneHD®的并发症和临床结果，以克服进行玻璃体切除术以治疗伴有增生性玻璃体视网膜病变（PVR）的牵张性和孔源性视网膜脱离的挑战。
方法：回顾性研究，我们在2014年8月至2023年8月期间对一个中心的患者进行了观察性研究.包括使用HSOOxaneHD®进行手术以治疗PVR的孔源性视网膜脱离或混合牵引和孔源性糖尿病性视网膜脱离的患者。无法参加随访的重症患者被排除在外。主要结果是在术后第一个月成功的视网膜附着。进行了描述性分析。
结果：在31例患者中，29例（93.5％）因孔源性视网膜脱离而接受了手术，2例（6.5％）因糖尿病性视网膜脱离而接受了手术。27例（87.1％）患者获得了主要解剖成功。在最后一次访问中,17人(56.6%)的视力优于20/400(范围，光感知的20/30)。随访结束时,22例(76.8%)患者视力稳定或改善。19例（61.3％）患者在使用HSO后需要降压滴眼液，12例（38.7％）在最后一次随访时仍需要降压滴眼液；3例（9.7％）患者需要额外的青光眼手术。
结论：HSO对于复杂的视网膜脱离病例是安全且有用的，特别是伴有下泪液和PVR的病例。眼部高血压是常见的，通常用低血压滴眼液进行临床控制。由于眼部并发症，建议术后密切随访。特别是眼内压升高和乳化。
方法：回顾性研究，我们在2014年8月至2023年8月期间对一个中心的患者进行了观察性研究.包括使用HSOOxaneHD®进行手术以治疗PVR的孔源性视网膜脱离或混合牵引和孔源性糖尿病性视网膜脱离的患者。无法参加随访的重症患者被排除在外。主要结果是在术后第一个月成功的视网膜附着。进行了描述性分析。
结果：在31例患者中，29例（93.5％）因孔源性视网膜脱离而接受了手术，2例（6.5％）因糖尿病性视网膜脱离而接受了手术。27例（87.1％）患者获得了主要解剖成功。在最后一次访问中,17人(56.6%)的视力优于20/400(范围，光感知的20/30)。随访结束时,22例(76.8%)患者视力稳定或改善。19例（61.3％）患者在使用HSO后需要降压滴眼液，12例（38.7％）在最后一次随访时仍需要降压滴眼液；3例（9.7％）患者需要额外的青光眼手术。
结论：HSO对于复杂的视网膜脱离病例是安全且有用的，特别是伴有下泪液和PVR的病例。眼部高血压是常见的，通常用低血压滴眼液进行临床控制。由于眼部并发症，建议术后密切随访。特别是眼内压升高和乳化。
